08:41 AM EDT, 06/17/2024 (MT Newswires) -- Grifols ( GRFS ) said Monday its subsidiary Biotest received approval from the US Food and Drug Administration for Yimmugo, an antibody injection, to treat primary immunodeficiencies.
Yimmugo is Biotest's first US-approved medicine and was developed using the company's new "Next Level" production facility, Grifols ( GRFS ) said.
Price: 7.07, Change: +0.07, Percent Change: +1.00